Form 10-Q - Quarterly report [Sections 13 or 15(d)]
SEC Accession No. 0001193125-26-215698
Filing Date
2026-05-11
Accepted
2026-05-11 07:20:38
Documents
76
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q apge-20260331.htm   iXBRL 10-Q 2274071
2 EX-31.1 apge-ex31_1.htm EX-31.1 18516
3 EX-31.2 apge-ex31_2.htm EX-31.2 18544
4 EX-32.1 apge-ex32_1.htm EX-32.1 14198
  Complete submission text file 0001193125-26-215698.txt   9375215

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT apge-20260331.xsd EX-101.SCH 1113602
80 EXTRACTED XBRL INSTANCE DOCUMENT apge-20260331_htm.xml XML 1810531
Mailing Address 221 CRESCENT ST. BUILDING 17, SUITE 102B WALTHAM MA 02453
Business Address 221 CRESCENT ST. BUILDING 17, SUITE 102B WALTHAM MA 02453 650-394-5230
Apogee Therapeutics, Inc. (Filer) CIK: 0001974640 (see all company filings)

EIN.: 934958665 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41740 | Film No.: 26960857
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)